COMPASS Pathways reports FY2021 net loss $71.7M; positive phase IIb TRD results, FDA meeting in April

COMPASS Pathways plc

2021-FY EPS reported -$1.79

Net loss for FY2021 was $71.7M ($1.79 loss per share), vs $60.3M in FY2020; Q4 net loss $25.7M.
Cash balance $273.2M at year-end 2021, up from $190.3M in 2020; well-capitalized for phase III.
Positive phase IIb trial of COMP360 psilocybin for TRD: rapid and sustained response at 25mg dose.
End-of-phase II meeting with FDA scheduled for late April 2022; phase III expected H2 2022.
New senior executives: Dr Guy Goodwin (CMO), Mike Falvey (CFO), Matt Owens (General Counsel).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.